P Palthera
Hormone Analogues

CJC-1295

Modified GRF(1-29) analogue / CJC-1295 with DAC / CJC-1295 without DAC

CJC-1295 is a synthetic investigated in early-phase human pharmacology studies and in GHRH-knockout rodent models. Published primary human research is limited to small Phase I/II pharmacokinetic and pharmacodynamic trials.

Add to comparison Subscribe
Abstract reference visual for Hormone Analogues.
Hormone Analogues
Classification
Synthetic GHRH analogue (with or without DAC)
Research stage
Phase I/II human pharmacology and rodent literature
Sequence
Modified 29-amino-acid GHRH analogue
Molecular weight
Approx. 3647 Da

Snapshot

Key takeaways

A three-bullet snapshot before reading the full dossier.

  1. 01

    Synthetic 29- of (1-29).

  2. 02

    Primary human data come from a small number of Phase I/II pharmacokinetic studies.

  3. 03

    Rodent data include -knockout mouse models.

Dossier overview

4

research areas

3

references

3

handling notes

01

Mechanism of action

Studies describe binding at with prolonged (when DAC-conjugated) and downstream stimulation of growth hormone and IGF-1 release in both rodent and human pharmacology research.

02

Research applications

  • Endocrine pharmacokinetic research
  • - binding studies
  • Peptide and comparison
  • Knockout-model rescue investigations

03

Study references

Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.

Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

2006

Teichman SL et al. · Journal of Clinical Endocrinology & Metabolism

Model
Phase I — healthy adult human volunteers
Sample
Not reported in abstract (small Phase I cohort)

Single and repeat CJC-1295 injections produced sustained 2–10-fold GH elevations and 1.5–3-fold IGF-1 elevations lasting multiple days in healthy adult volunteers.

PMID 16352683 DOI 10.1210/jc.2005-1536

Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse

2006

Alba M et al. · American Journal of Physiology — Endocrinology and Metabolism

Model
In vivo — GHRH knockout mice
Sample
Not reported in abstract

Daily CJC-1295 administration restored body weight, body length, and composition in -deficient mice and was associated with somatotroph proliferation.

PMID 16822960 DOI 10.1152/ajpendo.00208.2006

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects

2009

Sackmann-Sala L et al. · Growth Hormone & IGF Research

Model
Human pharmacology — healthy young adult men
Sample
n=11

Observed changes in serum protein profiles after CJC-1295 administration, identified as candidate biomarkers of GH/IGF-1 axis activation.

PMID 19386527 DOI 10.1016/j.ghir.2009.03.001

Evidence caveats

  • Human data come from small early-phase trials; long-term safety and efficacy in humans have not been established in peer-reviewed literature.
  • Some commercial-product analyses have flagged purity variation in research-grade material.

04

Storage and handling

Maintain under controlled laboratory storage and avoid repeated temperature variation.

  • Maintain chain-of-custody notes for comparison studies.
  • Avoid repeated variation unless protocol documentation supports it.
  • Separate research inventory from non-research materials.

05

Related reading

research

Research summary

Signalling

Receptor Signalling Context for Peptide Fragments

A research-context overview of peptide fragments studied for receptor-level signalling behaviour.

7 min

Read article
View full Hormone Analogues